Reversibility of monensin inhibition of oligosaccharide processing of human fibronectin.
Monensin impairs oligosaccharide processing in fibronectin primarily by inhibiting the conversion of oligosaccharides from the high mannose type to the complex type. The separate effects of monensin and cations on alpha-mannosidase activity in fibroblasts were examined using an in vitro assay system. The results indicated that monensin did not directly inhibit alpha-mannosidase activity in vitro, although prior treatment of fibroblasts with monensin caused an irreversible suppression of enzyme activity. The reversibility of monensin action on oligosaccharide processing was also examined. Analyses using concanavalin A (ConA) Sepharose affinity chromatography showed that the inhibitory action of monensin on oligosaccharide processing was biologically reversible. A progressive return to complex type oligosaccharides began about 11 h after the removal of the monensin. These composite results indicate that the reversibility of monensin action on oligosaccharide processing in fibronectin may be attributed to the restoration of enzyme activity, although the mechanism by which restoration occurs remains to be deciphered.
D002118:Calcium / Q000494:pharmacology; D002478:Cells, Cultured; D002846:Chromatography, Affinity; D003208:Concanavalin A; D005347:Fibroblasts / Q000201:enzymology / Q000378:metabolism; D005353:Fibronectins / Q000378:metabolism*; D005663:Furans / Q000494:pharmacology*; D006801:Humans; D008358:Mannose / Q000378:metabolism; D008361:Mannosidases / Q000037:antagonists & inhibitors; D008985:Monensin / Q000494:pharmacology*; D009844:Oligosaccharides / Q000378:metabolism*; D011188:Potassium / Q000494:pharmacology; D012867:Skin / Q000166:cytology; D012964:Sodium / Q000494:pharmacology
D005353:Fibronectins; D005663:Furans; D009844:Oligosaccharides; D003208:Concanavalin A; D008985:Monensin; D012964:Sodium; D008361:Mannosidases; D008358:Mannose; D011188:Potassium; D002118:Calcium